Korro Bio KRRO
NASDAQ KRRO
$13.06 +0.13 (+1.01%)
As of: Sep 10, 2026 · 3:59 PM EDT

Korro Bio (KRRO) Other Non-Current Assets (2018 - 2026)

Korro Bio's (KRRO) quarterly Other Non-Current Assets came in at $2.5 million in Q2 2026, down 23.12% on a YoY basis from $3.2 million in Q2 2025, and up 2.53% quarter-over-quarter from $2.4 million in Q1 2026.

Analysis

Korro Bio (KRRO) Other Non-Current Assets (2018 - 2026) Analysis & Trends

Korro Bio (KRRO) has reported Other Non-Current Assets for 9 consecutive years, with $2.5 million the latest figure, recorded in Q2 2026.

  • For the quarter ending Q2 2026, Other Non-Current Assets fell 23.12% year-over-year to $2.5 million; the trailing twelve-month figure through Jun 2026 stood at $2.5 million (down 23.12% YoY), and the FY2025 full-year result was $2.5 million, down 27.42% from the prior year.
  • Other Non-Current Assets rose to $2.5 million in Q2 2026 per KRRO's latest filing, from $2.4 million in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $7.0 million in Q4 2023 and bottomed at $1.7 million in Q1 2022.
  • Historically, Other Non-Current Assets has averaged $3.0 million across 5 years, with a median of $2.8 million in 2025.
  • The sharpest annual moves came in 2022 and 2024: Other Non-Current Assets jumped 202.77% in 2022, then slumped 51.13% in 2024.
  • Over 5 years, Other Non-Current Assets stood at $5.1 million in 2022, then jumped by 35.48% to $7.0 million in 2023, then sank by 51.13% to $3.4 million in 2024, then fell by 27.42% to $2.5 million in 2025, then fell by 0.08% to $2.5 million in 2026.
  • According to Business Quant data, Other Non-Current Assets over the past three periods registered $2.5 million, $2.4 million, and $2.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Other Non-Current Assets (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn 12.98 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn 4.75 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn 1.25 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn 2.31 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn 124.00 Mn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn 618.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn 65.13 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn 831.80 Mn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn 29.59 Mn
10 Korro Bio 231.15 Mn 116.12 Mn - 2.47 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 2.47 Mn
Mar 31, 2026 2.41 Mn
Dec 31, 2025 2.47 Mn
Sep 30, 2025 3.17 Mn
Jun 30, 2025 3.21 Mn
Mar 31, 2025 3.41 Mn
Dec 31, 2024 3.41 Mn
Sep 30, 2024 3.41 Mn
Jun 30, 2024 3.41 Mn
Mar 31, 2024 3.41 Mn
Dec 31, 2023 6.97 Mn
Sep 30, 2023 1.97 Mn
Jun 30, 2023 1.96 Mn
Mar 31, 2023 1.70 Mn
Dec 31, 2022 5.14 Mn
Sep 30, 2022 1.70 Mn
Jun 30, 2022 1.70 Mn
Mar 31, 2022 1.70 Mn
Dec 31, 2021 1.70 Mn
Sep 30, 2021 1.73 Mn